AU2013329348A1 - Laquinimod for reducing thalamic damage in multiple sclerosis - Google Patents
Laquinimod for reducing thalamic damage in multiple sclerosis Download PDFInfo
- Publication number
- AU2013329348A1 AU2013329348A1 AU2013329348A AU2013329348A AU2013329348A1 AU 2013329348 A1 AU2013329348 A1 AU 2013329348A1 AU 2013329348 A AU2013329348 A AU 2013329348A AU 2013329348 A AU2013329348 A AU 2013329348A AU 2013329348 A1 AU2013329348 A1 AU 2013329348A1
- Authority
- AU
- Australia
- Prior art keywords
- laquinimod
- subject
- thalamic
- afflicted
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017203896A AU2017203896A1 (en) | 2012-10-12 | 2017-06-08 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 | |
| US61/713,256 | 2012-10-12 | ||
| PCT/US2013/064061 WO2014058979A2 (en) | 2012-10-12 | 2013-10-09 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017203896A Division AU2017203896A1 (en) | 2012-10-12 | 2017-06-08 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013329348A1 true AU2013329348A1 (en) | 2015-05-28 |
Family
ID=50475887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013329348A Abandoned AU2013329348A1 (en) | 2012-10-12 | 2013-10-09 | Laquinimod for reducing thalamic damage in multiple sclerosis |
| AU2017203896A Abandoned AU2017203896A1 (en) | 2012-10-12 | 2017-06-08 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017203896A Abandoned AU2017203896A1 (en) | 2012-10-12 | 2017-06-08 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (OSRAM) |
| EP (1) | EP2961406A4 (OSRAM) |
| JP (1) | JP2015533163A (OSRAM) |
| KR (1) | KR20150080509A (OSRAM) |
| CN (1) | CN105263325A (OSRAM) |
| AR (1) | AR092993A1 (OSRAM) |
| AU (2) | AU2013329348A1 (OSRAM) |
| BR (1) | BR112015007782A2 (OSRAM) |
| CA (1) | CA2884272A1 (OSRAM) |
| CL (2) | CL2015000732A1 (OSRAM) |
| EA (1) | EA201590726A1 (OSRAM) |
| HK (1) | HK1218865A1 (OSRAM) |
| IL (1) | IL237745A0 (OSRAM) |
| MX (1) | MX2015004564A (OSRAM) |
| PE (1) | PE20151435A1 (OSRAM) |
| SG (1) | SG11201501874TA (OSRAM) |
| TW (1) | TW201420101A (OSRAM) |
| WO (1) | WO2014058979A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140235670A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries, Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| HK1225972A1 (zh) * | 2013-12-20 | 2017-09-22 | Teva Pharmaceutical Industries Ltd. | 利用拉喹莫德来延缓亨廷顿氏病的进展 |
| SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| KR20190064583A (ko) * | 2016-09-13 | 2019-06-10 | 인테크린 테라퓨틱스, 아이엔씨. | Chs-131로 다발성 경화증의 치료 |
| SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076681A2 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| CA2657716A1 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Cholanic acid amides |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010147665A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| AU2010282948C1 (en) * | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| EP2648732A4 (en) * | 2010-12-07 | 2014-04-30 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS |
| WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| HK1199820A1 (en) * | 2011-10-12 | 2015-07-24 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201420101A (zh) | 2014-06-01 |
| US20160296511A1 (en) | 2016-10-13 |
| WO2014058979A2 (en) | 2014-04-17 |
| US20140107154A1 (en) | 2014-04-17 |
| KR20150080509A (ko) | 2015-07-09 |
| WO2014058979A8 (en) | 2015-04-16 |
| AU2017203896A1 (en) | 2017-06-29 |
| MX2015004564A (es) | 2015-07-21 |
| EP2961406A4 (en) | 2017-01-04 |
| HK1218865A1 (zh) | 2017-03-17 |
| CA2884272A1 (en) | 2014-04-17 |
| EP2961406A2 (en) | 2016-01-06 |
| PE20151435A1 (es) | 2015-10-15 |
| SG11201501874TA (en) | 2015-05-28 |
| BR112015007782A2 (pt) | 2017-07-04 |
| CN105263325A8 (zh) | 2017-07-14 |
| CL2015000732A1 (es) | 2015-08-07 |
| CL2016002873A1 (es) | 2017-04-17 |
| AR092993A1 (es) | 2015-05-13 |
| WO2014058979A3 (en) | 2015-08-20 |
| CN105263325A (zh) | 2016-01-20 |
| EA201590726A1 (ru) | 2015-10-30 |
| JP2015533163A (ja) | 2015-11-19 |
| IL237745A0 (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103260624B (zh) | 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途 | |
| US20160296511A1 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| DK2442651T3 (en) | Treatment of multiple sclerosis with laquinimod | |
| AU2013256352A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| US20180064702A1 (en) | Treatment of progressive forms of multiple sclerosis with laquinimod | |
| US9662322B2 (en) | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |